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The transforming proteins (~21) of Harvey and Kirsten sarcoma viruses threonine kinase activity, which 
phosphorylates threonine 59 of the p21 proteins themselves. A tridecapeptide: 
Arg-Arg-Leus6 -Asp-Thr-Thr5g-Gly-Gln-Glu-Tyr-Ser-Ala66 
containing residues 56-66 of p21 is phosphorylated solely on tyrosine by the epidermal growth factor 
(EGF)-stimulated tyrosine kinase of A431 cell membranes. &Values of 240 and 80 PM and V,,, values 
of 1.7 and 0.1 nmol.min-‘.mg-’ were obtained in the presence and absence of EGF, respectively. 
Epidermal growth factor receptor Harvey virus oncogene Kirsten virus oncogene 
Protein p2I Phosphothreonine Phosphotyrosine 
1. INTRODUCTION 
The transforming proteins of many retroviruses 
possess the unusual ability to phosphorylate 
themselves and other proteins on tyrosine residues. 
Thus both the pp60 protein of Rous sarcoma virus 
[I] and the pp120 protein of Abelson leukemia 
virus [2] have associated tyrosine kinase activity. 
The observation that temperature sensitive muta- 
tions in both proteins affect kinase activity and 
transforming ability simultaneously suggests that 
tyrosine phosphorylation is intimately involved in 
the mechanism of transformation [3,4]. 
nucleotides to the p21 of a mutant Kirsten virus 
temperature-sensitive for transformation is ther- 
molabile [7]. The sequence surrounding threonine 
59 in p21 from both Harvey and Kirsten virus [8,9] 
is: 
In contrast, the transforming proteins (~21) of 
Harvey and Kirsten sarcoma viruses possess 
threonine kinase activity [5]. The only reported ac- 
ceptor site is threonine 59 of the p21 protein itself 
[5,6], and only GTP and dGTP can act as 
phosphate donors [5]. Although there is no direct 
evidence to connect threonine phosphorylation 
with transformation, binding of guanine 
The recognition site for tyrosine phosphoryla- 
tion appears to be a sequence of acidic amino acids 
immediately N-terminal to the modified tyrosine 
[lo-121. To test whether the p21 Glu-Glu-Tyr se- 
quence can be recognized by tyrosine kinases we 
have synthesized a peptide corresponding to 
residues 56-66 of ~21, with 2 arginines attached to 
its N-terminus to permit separation from ATP and 
phosphate by binding to phosphocellulose paper 
[13]. We report here that this peptide is 
phosphorylated solely on tyrosine by the EGF- 
stimulated tyrosine kinase of A431 cell 
membranes. 
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2. MATERIALS AND METHODS 
A431 cell membranes were prepared and their 
protein concentrations determined as in [ 141 except 
that Ca*+ was omitted from the harvesting buffer 
to prevent Ca’+-dependent proteolysis of the EGF- 
receptor [ 151. EGF-(r was prepared as in [ 161. 
The tridecapeptide: 
Arg-Arg-Leu-Asp-Thr-Thr-Gly-Gln-Glu- 
Glu-Tyr-Ser-Ala 
was synthesized by the solid phase procedure in 
[17], except that the first amino acid was coupled 
to the chloromethyl polystyrene resin as in [I 81 and 
the peptide cleaved in HF. The free peptide 
(80 mg) was desalted in 0.1 M acetic acid on a 
Biogel P-2 column (1 x 85 cm) at 30 ml/h. The 
peak fractions were further purified by reverse- 
phase HPLC on a column of Ultrasphere oc- 
tadecylsilica (15 cm x 4.6 mm i-d.) in 0.2% HFBA 
with a linear gradient of acetonitrile (0-50~0) at 
1 ml/min. 
The peptide was phosphorylated for 5 min at 
30°C in 30~1 of 20 mM Na + HEPES (pH 7.4), 
2 mM MnC12, 0.2% Nonidet P40, 10pM 
Zn(acetate)z, 5 mM 2-mercaptoethanol, 50 FM 
[y-32P]ATP (20 Cilpmol) and 5-10 Fg A43 1 cell 
membranes, separated from the reaction mixture 
by binding to P81 phosphocellulose paper and 
counted as in [14]. Recovery of phosphorylated 
tridecapeptide (purified by anion exchange 
chromatography 1191) in this procedure was 99%. 
To identify the phospho~ino acids present, 
samples of the anion exchange-purified peptide 
(2ooo cpm) were hydrolysed and the 
phosphoamino acids separated by thin-layer elec- 
trophoresis on celluiose thin layers (Merck, Darm- 
stadt) [20]. 2 gg each of phosphoserine (Sigma), 
phosphothreonine (Sigma) and phosphotyrosine 
(synthesized by US) were run as markers. 
Phosphoamino acids were detected by 
autoradiography (8 h) with a DuPont intensifying 
screen, and the marker amino acids were visualized 
with ninhydrin. 
3. RESULTS 
The trizecapeptide: 
Arg-Arg-Leu-Asp-Thr-Thr-Gly-GIn-Glu- 
Glu-Tyr-Ser-Ala 
258 
consisting of amino acids 56-66 of Harvey p21 
with 2 added arginines at the N-terminus, was syn- 
thesized as in section 2, desalted on a Biogel P-2 
column and further purified by reverse-phase 
HPLC (fig.1). Amino acid analysis [21] of the in- 
dicated peptide yielded the correct composition of 
Asp (l.O), Thr (2.0), Ser (l.O), Glu (3-l), Gly (l.O), 
Ala (l.l), Leu (l.l), Tyr (1.0) and Arg (1.7). 
The tridecapeptide was phosphorylated by A43 1 
cell membranes. Double reciprocal plots of the ef- 
fect of peptide concentration on reaction rate in 
the presence and absence of EGF- were linear 
(fig.2). EGF-cu stimulated the reaction -2O-fold by 
increasing the maximum velocity of phosphoryla- 
tion (table 1). A 2-3-fold increase in & was also 
observed. 
The tridecapeptide contains 4 potential 
phosphorylation sites, namely one serine, two 
threonines and one tyrosine. When partial acid 
hydrolysates of the peptide, phosphorylated in the 
o.ool 00 
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Fig.1. Purification of the Harvey p21 tridecapeptide. 
The crude tridecapeptide was desalted on a Biogel P-2 
column, and further purified by reverse-phase HPLC on 
an Ultrasphere ODS column. The Harvey tridecapeptide 
eiuted at 27.5 min. Experimental details are given in 
section 2. 
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Fig.2. Double reciprocal plot for peptide 
phosphorylation. Peptide phosphorylation was assayed 
at 48-36OpM as in section 2 with (0) and without (m) 
3 pg EGF_cr/ml. Lines of best fit were constructed with 
the Km and V,,,, values presented in table 1 expt 2. 
Kinetic constants for phosphorylation of the Harvey 
peptide 
Peptide K,,, + SE V max + SE 
OcM) (nmol. min-’ . mg-‘) 
+ EGF - EGF + EGF - EGF 
R.R.L.D.T.T.G.Q.E.E.Y.S.A. (Harvey peptide) 
Expt 1 243 + 36 79 * 39 1.65 + 0.13 0.09 + 0.01 
Expt 2 242 f 43 91 + 49 2.25 f 0.25 0.11 f 0.02 
R.L.I.E.D.N.E.Y.T.A.R.Q.E.amide (Rous 
peptide) [ 141 
4300 3500 6.4 1.4 
R.R.L.E.E.E.E.E.A.Y.G (Gastrin peptide) [14] 
150 300 1.7 0.4 
Peptide phosphorylation was assayed with 2 separate 
membrane preparations as in section 2. K,,, and V,,,,, 
values were obtained by fitting the data to the 
Michaelis-Menten equation with a weighted least 
squares program [24] 
pH 1.9 
Fig.3. Phosphoamino acid composition of the Harvey p21 tridecapeptide. An amino acid hydrolysate of the 
phosphorylated peptide, labelled in the absence (A) and presence (B) of EGF-cx, was analyzed by two-dimensional 
electrophoresis [20]: Markers were visualized with ninhydrin; (x) origin. 
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presence and absence of EGF-Lu, were subjected to 
two-dimensional electrophoresis, autoradiography 
revealed that radioactivity in both cases was incor- 
porated only into phosphotyrosine (fig.3). 
4. DISCUSSION 
A peptide containing residues 56-66 of the ~21 
transforming proteins of Harvey and Kirsten 
murine sarcoma viruses was phosphorylated by the 
EGF-stimulated tyrosine kinase of A43 1 cell mem- 
branes. Values of both K,,, and m~imum velocity 
in the presence of EGF-LY were -2O-fold less than 
the values obtained for a peptide comprising 
residues 412-424 of the p60 transforming protein 
of Rous avian sarcoma virus, but very similar to 
the values obtained for a peptide containing 
residues 5-13 of human gastrin 17 (table 1). In the 
absence of EGF-cu, &, and maximum velocity were 
consistently lower than the values obtained for the 
Rous and gastrin peptides (table 1). 
Two-dimensional electrophoresis of acid 
hydrolysates of phosphorylated peptide revealed 
that phosphotyrosine was the only labelled amino 
acid. This observation confirms the finding with 
the SRC peptide that the EGF-receptor kinase is 
absolutely specific for tyrosine [ 111. In addition it 
raises the intriguing question of whether tyrosine 
64 of intact ~21 can also be phosphorylated by 
ATP-dependent kinases in vivo. However, no 
tyrosine kinase activity has yet been demonstrated 
in cells transformed by Harvey virus, and in fact 
previous studies with 32Pi labelling of mouse cells 
transformed by Harvey or Kirsten sarcoma virus 
[6], or with [y-“P]GTP labelling of partially 
purified ~21 [S] have identified threonine 59 as the 
major phosphorylation site both in vivo and in 
vitro. The proximity of the two residues suggests 
that phosphorylation at tyrosine 64 might in- 
fluence phosphorylation at threonine 59. If the lat- 
ter modification indeed represents a phosphoen- 
zyme intermediate in the ~21 threonine kinase ac- 
tivity [5], then tyrosine phosphorylation could 
modulate that activity in the same way that 
phosphorylation of both middle T antigen and the 
SRC protein increases their tyrosine kinase activity 
[22,23]. Thus the results presented here suggest the 
possibility of a direct connection between two of 
the possible mechanisms of viral transformation, 
namely tyrosine and threonine phosphorylation. 
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